Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀڱðæºÎ ½Å°æ³»ºÐºñ¾ÏÀÇ ÀÓ»óÀû Ư¡°ú Ä¡·á °á°ú Clinical Characteristics and Treatment Results of Neuroendocrine Carcinoma of Uterine Cervix

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2004³â 22±Ç 2È£ p.124 ~ 129
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿Á¹è/Kim OB ±èÁøÈñ/Â÷¼øµµ/ÃÖÅÂÁø/¿¹Áö¿ø

Abstract

¸ñ Àû: ÀڱðæºÎÀÇ ½Å°æ³»ºÐºñ¾ÏÀº ºñ±³Àû µå¹® ÁúȯÀ¸·Î º»¿ø¿¡¼­ ±¤ÇÐÇö¹Ì°æ ¹× ¸é¿ªÁ¶Á÷È­ÇÐÀû Áø´ÜÀ» ¹Þ°í, Ä¡·á¹ÞÀº ȯÀÚ¸¦ ´ë»óÀ¸·Î ÀÓ»óÀû Ư¡, ¿¹ÈÄ ¹× Ä¡·á¹æħ¿¡ ´ëÇØ ¾Ë¾Æº¸°íÀÚ ÇÑ´Ù.

´ë»ó ¹× ¹æ¹ý: 1994³â 5¿ùºÎÅÍ 2001³â 10¿ù±îÁö º»¿ø¿¡¼­ Á¶Á÷ÇÐÀûÀ¸·Î ÀڱðæºÎ ½Å°æ³»ºÐºñ¾ÏÀ¸·Î Áø´Ü¹ÞÀº ȯÀÚ 13¿¹¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. ȯÀÚÀÇ Æò±Õ ¿¬·ÉÀº 56¼¼(32¢¦78¼¼)À̸ç, º´±âºÐÆ÷´Â IB 5¸í, IIA 5¸í, IIB 3¸íÀ̾ú´Ù. ¼ö¼úÀ» ½ÃÇàÇÑ È¯ÀÚ´Â 5¸íÀ¸·Î ÀÌ Áß 3¸íÀº ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á¸¦ Ãß°¡ÇÏ¿´´Ù. ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÑ È¯ÀÚ´Â 9¸íÀ̸ç, ÀÌ Áß 1¸íÀº ¹æ»ç¼±Ä¡·á ÈÄ ±Ù¸·¿Ü ÀÚ±ÃÀûÃà¼úÀ» ½ÃÇàÇÏ¿´°í, ¼±Çà ȤÀº µ¿½ÃÇ×¾ÏÈ­Çпä¹ýÀ» ½ÃÇàÇÑ È¯ÀÚ´Â 9¸íÀ̾ú´Ù. ¹æ»ç¼±Ä¡·á´Â º´±â¿¡ µû¶ó¼­ Àü°ñ¹ÝºÎ 4,500¢¦5,400 cGy±îÁö ¿ÜºÎÁ¶»ç ÈÄ, °­³»Á¶»ç¸¦ ÁÖ 2ȸ, A point¿¡ 1ȸ´ç 500 cGy·Î 3,000¢¦3,500 cGy¸¦ Á¶»çÇÏ¿´´Ù.

°á °ú: ÃßÀû°üÂû±â°£Àº 3°³¿ù¿¡¼­ 104°³¿ù·Î Æò±Õ 36°³¿ùÀ̾ú´Ù. 5³â »ýÁ¸À²Àº 61.5%À̾úÀ¸¸ç, º´±âº° 5³â »ýÁ¸À²Àº º´±â IB 60.0%, IIA 60.0%, IIB 66.7%·Î Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù(p=0.99). Àüü 13¸í Áß 5¸í(38.5%)ÀÌ »ç¸ÁÇÏ¿´À¸¸ç, ÀÌ Áß 4¸í¿¡¼­ °ñ¹ÝºÎÀ§ ¹× º¹ºÎ´ëµ¿¸Æ ÁÖÀ§ ÀÓÆÄÀý ÀüÀÌ°¡ È®ÀεǾú°í, ÀÌµé ¸ðµÎ ¿ø°ÝÀå±â ÀüÀÌ·Î »ç¸ÁÇÏ¿´´Ù. »ç¸ÁÀÚÀÇ Æò±Õ»ýÁ¸±â°£Àº 6°³¿ùÀ̸ç, ÀÓÆÄÀý ÀüÀÌ À¯¹«¿¡ µû¶ó¼­ Åë°èÀûÀ¸·Îµµ À¯ÀÇÇÑ Â÷ÀÌ(p=0.0001)¸¦ °üÂûÇÒ ¼ö ÀÖ¾ú´Ù. ³ª¸ÓÁö 8¸íÀº ¹«º´»ýÁ¸ ÁßÀÌ´Ù.

°á ·Ð: ÀڱðæºÎÀÇ ½Å°æ³»ºÐºñ¾ÏÀº Ãʱ⺴±âÀÏÁö¶óµµ ÀÓÆÄÀýÀüÀÌ¿Í ¿ø°ÝÀüÀÌ°¡ ¸¹°í º´ÀÇ ÁøÇàÀÌ ±Þ¼ÓÈ÷ ÀÌ·ç¾îÁö´Â ¾ç»óÀ» º¸À̹ǷΠ±¹¼ÒÄ¡·áÀÎ ¼ö¼úÀ̳ª ¹æ»ç¼±Ä¡·á¿Í ÇÔ²² Àü½ÅÀûÀÎ º¹ÇÕÇ×¾ÏÈ­Çпä¹ýÀ» º´ÇàÇÏ´Â °ÍÀÌ ÁÁÀ» °ÍÀ¸·Î »ý°¢µÇ¸ç ÀûÀýÇÑ º´ÇÕÄ¡·á°¡ ȯÀÚÀÇ »ýÁ¸À²À» Çâ»ó½Ãų °ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose: To evaluate the clinical findings, prognosis and treatment strategy of patients with neuroendocrine carcinoma of cervix.

Materials and Methods: Thirteen patients with neuroendocrine carcinoma of cervix were included in this study, as confirmed histologically and immunohistochemically at the Dongsan Medical Center, Keimyung University, between May 1944 and October 2001. The mean age of patients was 56 years with a range of 32 to 78 years of age. According to the FIGO staging system, there were 5 patients with stage IB carcinoma, 5 patients with IIA, and 3 patients with stage IIB. Four patients underwent radical hysterectomy with pelvic lymphadenectomy, 3 of these patients also received postoperative radiotherapy, and one patient underwent extrafascial hysterectomy after radiotherapy. Primary radiotherapy was done in 9 patients, and 3 were irradiated postoperatively. Nine patients received chemotherapy, 7 received neoadjuvant and 2 received concurrent chemoradiotherapy. The radical purpose of radiotherapy consisted of external irradiation to the whole pelvis (4,500¢¦5,400 cGy) and intracavitary irradiation (3,000¢¦3,500 cGy).

Results: The mean follow up duration was 36 months with a range of 3 to 104 months. The overall 5-year survival rate was 61.5% and the 5-year survival rates for stage IB, IIA, IIB were 60.0%, 60.0%, and 66.7% respectively (p=0.99). Eight patients are still alive without disease, and all of the 5 patients with recurrence are dead due to distant metastasis.

Conclusion: Neuroendocrine carcinoma of cervix is highly aggressive, with early lymphatic dissemination and a high rate of distant recurrence. Therefore, an aggressive therapeutic strategy is required to obtain pelvic and distant disease control. Multimodal therapy should be considered at the time of initial diagnosis.

Å°¿öµå

ÀڱðæºÎ¾Ï;½Å°æ³»ºÐºñ¾Ï;Neuroendocrine carcinoma;Uterine cervical carcinoma

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS